Apimeds Pharmaceuticals Us, INC. (APUS) — SEC Filings

Overview

Apimeds Pharmaceuticals Us, INC. (APUS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: Apimeds Pharmaceuticals US, Inc. filed an 8-K on March 25, 2026, reporting significant corporate governance changes effective March 20, 2026. The filing includes amendments to its bylaws (Item 5.03) and details regarding departures or appointments of officers/directors and their compensation (Item 5

Sentiment Summary

Across 23 filings, the sentiment breakdown is: 22 neutral, 1 mixed. The dominant filing sentiment for Apimeds Pharmaceuticals Us, INC. is neutral.

Filing Type Overview

Apimeds Pharmaceuticals Us, INC. (APUS) has filed 2 8-K/A, 8 8-K, 3 10-Q, 1 10-K/A, 1 10-K, 7 S-1/A, 1 S-1 with the SEC between Sep 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (23)

• 8-K/A Filing — 8-K/A · Apr 9, 2026
• 8-K Filing — 8-K · Mar 26, 2026
• Apimeds Amends Bylaws, Reports Officer Changes on March 20, 2026 — 8-K · Mar 25, 2026
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on March 25, 2026, reporting significant corporate governance changes effective March 20, 2026. The filing include
• Apimeds Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Dec 10, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an amendment (8-K/A) on December 10, 2025, to its Form 8-K originally filed on December 1, 2025. This amendment pertains
• Apimeds Pharmaceuticals Files 8-K with Multiple Material Events — 8-K · Dec 2, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on December 2, 2025, reporting several material events as of December 1, 2025. These include entering into a mater
• 8-K Filing — 8-K · Nov 18, 2025
• Apimeds' Losses Mount Amid R&D Surge, IPO Boosts Cash to $7M — 10-Q · Nov 12, 2025 Risk: high
  Apimeds Pharmaceuticals US, Inc. (APUS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $4,845,845, up from $
• Apimeds Pharmaceuticals Files 8-K for Bylaws and Financials — 8-K · Oct 16, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on October 16, 2025, reporting amendments to its Articles of Incorporation or Bylaws and financial statements. The
• Apimeds Pharmaceuticals Files Q2 2025 10-Q — 10-Q · Aug 19, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2025. The company, incorporated in Delaware with its prin
• Apimeds Pharmaceuticals Files 8-K — 8-K · Jul 16, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on July 16, 2025, reporting events as of July 15, 2025. The filing is a current report pursuant to Section 13 or 1
• Apimeds Pharmaceuticals Reports Officer and Director Changes — 8-K · Jun 5, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on June 5, 2025, reporting changes effective May 30, 2025. The filing indicates a departure of directors or certai
• Apimeds Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 20, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware with its pri
• Apimeds Pharmaceuticals Files 8-K on Agreements and Equity Sales — 8-K · May 12, 2025 Risk: medium
  On May 8, 2025, Apimeds Pharmaceuticals US, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement,
• Apimeds Pharmaceuticals Files 10-K Amendment — 10-K/A · May 2, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed an amendment (Amendment No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2024. The filing,
• Apimeds Pharmaceuticals Files 2024 10-K Report — 10-K · Apr 15, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Delaware with it
• Apimeds Pharmaceuticals Files S-1/A Amendment — S-1/A · Feb 10, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on February 10, 2025, for its registration statement (No. 333-282324). The company, incorporated in De
• Apimeds Pharmaceuticals Files S-1/A Amendment — S-1/A · Feb 6, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on February 6, 2025, for its registration statement. The company, incorporated in Delaware, is based i
• Apimeds Pharmaceuticals Files S-1/A Amendment — S-1/A · Jan 29, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on January 29, 2025, for its registration statement (No. 333-282324). The company, incorporated in Del
• Apimeds Pharmaceuticals Files S-1/A Amendment — S-1/A · Jan 10, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on January 10, 2025, for its registration statement. The company, incorporated in Delaware, is in the
• Apimeds Pharmaceuticals Files S-1/A Amendment — S-1/A · Dec 20, 2024 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on December 20, 2024, for its registration statement (No. 333-282324). The company, incorporated in De
• Apimeds Pharmaceuticals Files IPO Amendment — S-1/A · Dec 9, 2024 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on December 9, 2024, for its initial public offering. The company, incorporated in Delaware, is seekin
• Apimeds Pharmaceuticals Files S-1/A Amendment — S-1/A · Nov 8, 2024 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on November 8, 2024, for its registration statement. The company, incorporated in Delaware, is in the
• Apimeds Pharmaceuticals Files S-1 for Public Offering — S-1 · Sep 25, 2024 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an S-1 registration statement on September 25, 2024, to register securities under the Securities Act of 1933. The company

Risk Profile

Risk Assessment: Of APUS's 19 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Apimeds Pharmaceuticals Us, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: N/A
• Net Income: -$4,845,845
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $6,986,617
• Operating Margin: N/A
• Total Assets: $9,250,036
• Total Debt: $1,089,384

Key Executives

• Erik Emerson

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and stringent regulatory requirements. Companies like Apimeds are focused on developing novel therapies, often requiring substantial capital to navigate clinical trials and gain FDA approval. The competitive landscape is intense, with established players and emerging biotechs vying for market share.

Top Tags

pharmaceuticals (12) · sec-filing (7) · ipo (4) · corporate-governance (2) · amendment (2) · equity-sale (2) · 10-Q (2) · quarterly-report (2) · annual-report (2) · ipo-process (2)

Key Numbers

• SEC File Number: 001-42545 — Identifier for Apimeds Pharmaceuticals US, Inc.
• EIN: 85-1099700 — Employer Identification Number for Apimeds Pharmaceuticals US, Inc.
• Net Loss: $4,845,845 — for the nine months ended September 30, 2025, a significant increase from $1,078,357 in 2024
• Cash: $6,986,617 — as of September 30, 2025, up from $3,455 at December 31, 2024, due to IPO proceeds
• Net Cash Proceeds from IPO: $11.9 million — generated on May 12, 2025, providing liquidity
• Total Assets: $9,250,036 — as of September 30, 2025, a substantial increase from $13,057 at December 31, 2024
• Accumulated Deficit: $9,237,769 — as of September 30, 2025, indicating historical losses
• Research and Development Expenses: $1,271,477 — for the nine months ended September 30, 2025, up from $0 in 2024
• General and Administrative Expenses: $3,601,034 — for the nine months ended September 30, 2025, up from $999,482 in 2024
• Shares of Common Stock Outstanding: 12,575,983 — as of November 12, 2025
• Commission File Number: 001-42545 — Identifies the company's SEC filings
• IRS Employer Identification No.: 85-1099700 — Company's tax identification number
• Fiscal Year End: 2024 — The period covered by the annual report.
• SIC Code: 2834 — Industry classification for Pharmaceutical Preparations.
• ZIP Code: 08425 — Part of the principal executive office address in Hopewell, NJ.

Frequently Asked Questions